TG Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of TG Therapeutics generated cash of -$31,413,000, which is more than the previous year. Cash used in financing activities reached the amount of $72,705,000 last year. Net change in cash is therefore -$9,359,000.
Cash Flow
| 2014 | -35.05M | -18.35M | 68.64M |
|---|---|---|---|
| 2015 | -44.69M | -24.68M | 68.72M |
| 2016 | -61.59M | 26.54M | 5.01M |
| 2017 | -93.76M | -8.20M | 133.65M |
| 2018 | -128.92M | 1.18M | 113.63M |
| 2019 | -132.80M | -718K | 204.21M |
| 2020 | -214.50M | -24.51M | 679.82M |
| 2021 | -295.63M | -332K | 41.41M |
| 2022 | -176.17M | -20.01M | -391K |
| 2023 | -31.41M | -50.65M | 72.70M |
0VGI.L Cash Flow Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 103.57M | 300.15M | 554.69M | 113.88M | 43.19M | 57.30M | 25.03M | 55.06M | 55.71M | 40.48M |
Operating activities | ||||||||||
Net income | 12.67M | -198.33M | -348.10M | -279.38M | -172.87M | -173.48M | -118.47M | -78.25M | -62.94M | -55.78M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 423K | 515K | 494K | 374K | 282K | 88K | 82.35K | 62.96K | 15.45K | 3.93K |
Stock-based compensation expense | 37.93M | 19.18M | 61.27M | 80.28M | 11.33M | 0 | 15.94M | 7.50M | 15.69M | 21.10M |
| Deferred income tax benefit | 37.93M | 19.18M | 61.27M | 80.28M | 11.33M | 0 | 15.94M | 7.50M | 15.69M | 21.10M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 1.38M | -1.38M | -6K | -11K | 14K | -24.61K | 102.16K | -100.50K | 0 |
Inventories | 0 | 0 | -15.99M | 6K | 11K | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 0 | -11.01M | 15.99M | 11.63M | -4.79M | 10.95M | 11.02M | 6.49M | 5.47M | -603.37K |
Cash generated by operating activities | -31.41M | -176.17M | -295.63M | -214.50M | -132.80M | -128.92M | -93.76M | -61.59M | -44.69M | -35.05M |
Investing activities | ||||||||||
Purchases Of Investments | -146.88M | -107.27M | -55.53M | -67.40M | -29.83M | -31.23M | -28.00M | -15.19M | -48.99M | -18.33M |
Investments In Property Plant And Equipment | 0 | -14K | -401K | -357K | -131K | -90K | -2.22K | -343.98K | -42.21K | -18.57K |
Acquisitions Net | 0 | 19.99M | -69K | 24.15M | 587K | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -50.65M | -20.01M | -332K | -24.51M | -718K | 1.18M | -8.20M | 26.54M | -24.68M | -18.35M |
Financing activities | ||||||||||
Common Stock Issued | 46.29M | 0 | 2.21M | 679.68M | 175.02M | 113.63M | 131.51M | 4.41M | 67.76M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 25M | -975K | -30M | 0 | 29.98M | 0 | 0 | 0 | 0 | -677.77K |
Cash used in financing activities | 72.70M | -391K | 41.41M | 679.82M | 204.21M | 113.63M | 133.65M | 5.01M | 68.72M | 68.64M |
Net Change In Cash | -9.35M | -196.57M | -254.54M | 440.81M | 70.68M | -14.10M | 31.68M | -30.03M | -652.45K | 15.22M |
Cash at end of period | 94.21M | 103.57M | 300.15M | 554.69M | 113.88M | 43.19M | 56.71M | 25.03M | 55.06M | 55.71M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |